<DOC>
	<DOCNO>NCT02661035</DOCNO>
	<brief_summary>This phase II trial use non-myeloablative cyclophosphamide/ fludarabine/total body irradiation ( TBI ) preparative regimen follow related unrelated donor stem cell infusion . The primary objective evaluate rate acute graft-versus-host disease ( GVHD ) grade II-IV chronic GVHD update GVHD prophylaxis tacrolimus mycophenolate mofetil ( MMF ) non-myeloablative preparative regimen person hematologic malignancy .</brief_summary>
	<brief_title>Allo HSCT Using RIC Hematological Diseases</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Leukemia , Plasma Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Age , Performance Status , Graft Criteria Age 0 70 year age Karnofsky score ≥ 70 % ( ≥ 16 year ) Lansky score ≥ 50 ( &lt; 16 year ) refer appendix III Patients ≥ 70 ≤ 75 year age may eligible HCTCI CoMorbidity score ≤ 2 refer appendix II Must ≥ 3 month prior myeloablative transplant , applicable 5/6 6/6 related donor match 78/8 HLAA , B , C , DRB1 allele match unrelated donor marrow and/or PBSC donor match per current institutional guideline Related donor evaluate collect per MT201214C ; Unrelated donor identify collect per usual procedure Eligible Diseases Acute Myeloid Leukemia ( AML ) : high risk CR1 ( evidence precede MDS , high risk cytogenetics , ≥ 2 cycle obtain CR , erythroblastic megakaryocytic leukemia , FLT3 ITD + ; CR2+ . All patient must CR defined hematological recovery , AND &lt; 5 % blast light microscopy within bone marrow cellularity ≥15 % . Very high risk pediatric patient AML : Patients &lt; 21 year , however , eligible ( M2 marrow ) &lt; 25 % blast marrow fail one cycle chemotherapy . Acute Lymphocytic Leukemia ( ALL ) : factor define high risk CR1 include limited cytogenetics demonstrate ( 9 ; 22 ) , ( 1:19 ) , ( 4 ; 11 ) , MLL rearrangement , hypodiploidy , IKZF1 abnormality ) , DNA index &lt; 0.81 , &gt; 1 cycle obtain CR presence minimal residual disease ( MRD ) . Patients CR2+ eligible . All patient must CR defined hematological recovery , AND &lt; 5 % blast light microscopy within bone marrow cellularity ≥15 % . Very high risk pediatric patient ALL : patient &lt; 21 year also consider high risk CR1 M2 M3 marrow day 42 initiation induction M3 marrow end induction . They eligible achieved complete remission . Chronic Myelogenous Leukemia exclude refractory blast crisis : To eligible first chronic phase ( CP1 ) patient must fail intolerant imatinib mesylate . Plasma Cell Leukemia initial therapy , achieve least partial remission Myelodysplasia ( MDS ) require transplant define : IPSS INT2 High Risk ; RIPSS High Very High ; WHO classification : RAEB1 , RAEB2 ; Severe Cytopenias : ANC &lt; 0.8 , Anemia thrombocytopenia require transfusion ; Poor poor risk cytogenetics base IPSS RIPSS definition ; therapyrelated MDS . Blasts must &lt; 5 % bone marrow aspirate morphology . Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma ( CLL/SLL ) , Marginal Zone BCell Lymphoma Follicular Lymphoma eligible disease progression/relapse within 12 achieve partial complete remission . Patients remission last &gt; 12 month , eligible least two prior therapy . Patients bulky disease ( nodal mass great 5 cm ) consider debulking chemotherapy transplant . Lymphoplasmacytic Lymphoma , MantleCell Lymphoma , Prolymphocytic Leukemia , NK cell malignancy eligible initial therapy CR1+ PR1+ . Large Cell NHL &gt; CR2/ &gt; PR2 : Patients CR2/PR2 initial short remission ( &lt; 6 month ) eligible . Lymphoblastic Lymphoma , Burkitt 's Lymphoma , highgrade NHL initial therapy stage III/IV CR1/PR1 progression stage I/II &lt; 1 year . Multiple Myeloma beyond PR2 : Patients chromosome 13 abnormality , first response last less 6 month , β2 microglobulin &gt; 3 mg/L , may consider protocol initial therapy . Myeloproliferative Syndromes Organ Function Criteria Adequate organ function define : Liver : AST ALT &lt; 5 x upper limit normal bilirubin &lt; 3 x upper limit normal Renal : Creatinine ≤ 2.0 mg/dl ( adult ) estimate glomerular filtration rate ( GFR ) ≥ 40 mL/min ( pediatrics ) . Adults creatinine &gt; 1.2 mg/dl history renal dysfunction must estimate glomerular filtration rate ( GFR ) &gt; 40 mL/min . Albumin &gt; 2.5 g/dL Cardiac : Absence decompensated congestive heart failure , uncontrolled arrhythmia leave ventricular ejection fraction &gt; 35 % . Pulmonary : DLCOcorr ≥ 40 % predict , absence O2 requirement . For child able cooperate PFTs , pulse oximetry without exercise attempt . If neither test obtain clearly state physician 's note . If recent mold infection ( e.g . aspergillus ) must minimum 30 day therapy responsive disease clear Infectious Disease Females child bear potential sexually active male must agree use adequate birth control study treatment Voluntary write consent ( adult parent/guardian presentation minor information sheet , appropriate ) Pregnant breast feeding . The agent use study include Pregnancy Category D : know cause harm fetus . Females childbearing potential must blood test urine study within 14 day prior registration rule pregnancy . Untreated active infection Active CNS disease Active HIV infection know HIV positive serology Congenital bone marrow failure syndrome Previous irradiation precludes safe administration additional dose 200 cGy TBI CML refractory blast crisis Intermediate high grade NHL , mantle cell NHL , Hodgkin disease progressive salvage therapy . Stable disease acceptable move forward provide nonbulky . Multiple myeloma progressive salvage chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AML</keyword>
	<keyword>ALL</keyword>
	<keyword>CML</keyword>
	<keyword>MDS</keyword>
	<keyword>CLL</keyword>
	<keyword>SLL</keyword>
	<keyword>NHL</keyword>
</DOC>